Abstract
Background: Osteosarcoma (OS) is a prevalent primary bone malignancy and its distal metastasis remains the main cause of mortality in OS patients. MicroRNAs (miRNAs) play critical roles during cancer metastasis.
Objective: Thus, elucidating the role of miRNA dysregulation in OS metastasis may provide novel therapeutic targets.
Methods: The previous study found a low miR-134 expression level in the OS specimens compared with paracancer tissues. Overexpression of miR-134 stable cell lines was established. Cell viability assay, cell invasion and migration assay and apoptosis assay were performed to evaluate the role of miR-134 in OS in vitro.
Results: We found that miR-134 overexpression inhibits cell proliferation, migration and invasion, and induces cell apoptosis in both MG63 and Saos-2 cell lines. Mechanistically, miR-134 targets the 3'-UTR of VEGFA and MYCN mRNA to silence its translation, which was confirmed by luciferase-reporter assay. The real-time PCR analysis illustrated that miR-134 overexpression decreases VEGFA and MYCN mRNA levels. Additionally, the overexpression of VEGFA or MYCN can partly attenuate the effects of miR-134 on OS cell migration and viability. Furthermore, the overexpression of miR-134 dramatically inhibits tumor growth in the human OS cell line xenograft mouse model in vivo. Moreover, bioinformatic and luciferase assays indicate that the expression of miR-134 is regulated by Interferon Regulatory Factor (IRF1), which binds to its promoter and activates miR-134 expression.
Conclusion: Our study demonstrates that IRF1 is a key player in the transcriptional control of miR-134, and it inhibits cell proliferation, invasion and migration in vitro and in vivo via targeting VEGFA and MYCN.
Keywords: IRF1, miR-134, VEGFA, MYCN, osteosarcoma, tumorigenesis.
Graphical Abstract
[http://dx.doi.org/10.1038/cdd.2013.125] [PMID: 24212931]
[http://dx.doi.org/10.1038/cdd.2009.69] [PMID: 19498445]
[http://dx.doi.org/10.4161/rna.20146] [PMID: 22664917]
[http://dx.doi.org/10.1007/s13277-015-3568-y] [PMID: 26002578]
[http://dx.doi.org/10.1038/mt.2011.53]
[http://dx.doi.org/10.1016/j.bbrc.2009.07.101] [PMID: 19632201]
[http://dx.doi.org/10.1016/j.omtn.2016.11.003] [PMID: 28325280]
[http://dx.doi.org/10.1016/j.gene.2015.11.040] [PMID: 26642897]
[http://dx.doi.org/10.18632/oncotarget.5192] [PMID: 26416415]
[http://dx.doi.org/10.1089/dna.2014.2629] [PMID: 25811077]
[http://dx.doi.org/10.1016/j.febslet.2015.08.047] [PMID: 26363097]
[http://dx.doi.org/10.1007/s10529-015-1941-y] [PMID: 26318721]
[http://dx.doi.org/10.1371/journal.pone.0087665] [PMID: 24498348]
[http://dx.doi.org/10.1158/1535-7163.MCT-13-0448] [PMID: 24258346]
[http://dx.doi.org/10.3892/ijo.2013.1844] [PMID: 23467648]
[http://dx.doi.org/10.1038/sj.onc.1210938] [PMID: 18026138]
[http://dx.doi.org/10.1016/S0092-8674(04)00045-5] [PMID: 14744438]
[http://dx.doi.org/10.1155/2012/359739] [PMID: 22550419]
[http://dx.doi.org/10.1155/2011/732690] [PMID: 21789031]
[http://dx.doi.org/10.1089/scd.2009.0112] [PMID: 19795981]
[http://dx.doi.org/10.1371/journal.pone.0080544] [PMID: 24260413]
[http://dx.doi.org/10.1007/s11914-011-0047-2] [PMID: 21360287]
[http://dx.doi.org/10.1097/CCO.0b013e3283622c1b] [PMID: 23666471]
[http://dx.doi.org/10.1016/j.critrevonc.2014.02.001] [PMID: 24613529]
[http://dx.doi.org/10.1016/j.canlet.2010.01.015] [PMID: 20153925]
[http://dx.doi.org/10.1016/j.canep.2011.08.002] [PMID: 21890444]
[http://dx.doi.org/10.1159/000011912] [PMID: 9778623]